Clinical Trials Logo

Hepatitis C, Chronic clinical trials

View clinical trials related to Hepatitis C, Chronic.

Filter by:

NCT ID: NCT01364090 Completed - Clinical trials for Hepatitis C, Chronic

A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3

ACTIVATE
Start date: June 2012
Phase: Phase 4
Study type: Interventional

This sudy will determine whether shortening treatment for hepatitis C is feasible, safe and effective for patients who are current injection drug users or receiving opiate substitution therapy and who are responding well to treatment early on.

NCT ID: NCT01360892 Recruiting - Chronic Hepatitis B Clinical Trials

Prediction of Incidence of Liver Cancer by Use of Real-time Tissue Elastography

PICTURE
Start date: September 2010
Phase: N/A
Study type: Observational

This is a multi-center cohort study in which the Real-time Tissue Elastography® measurements will predict prospectively the incidence of hepatocellular carcinoma, the incidence and severity of gastroesophageal varices ascites and decompensated cirrhosis in hepatitis B or C patients.

NCT ID: NCT01360879 Recruiting - Chronic Hepatitis B Clinical Trials

Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease

FIBROELAST
Start date: September 2010
Phase: N/A
Study type: Observational

This is a multi-center cross-sectional study in which the Real-time Tissue Elastography® measurements will be collected prospectively from patients with chronic hepatitis B or C virus presenting for liver biopsy.

NCT ID: NCT01359644 Completed - Chronic Hepatitis C Clinical Trials

Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care

Start date: June 2011
Phase: Phase 2
Study type: Interventional

The purpose of the study is to determine whether therapy with the combination of PSI-7977 and daclatasvir (BMS-790052) with or without ribavirin is effective in treating hepatitis C virus (HCV) infection when given for 12 or 24 weeks as measured by sustained virologic response with undetectable HCV RNA 12 weeks post treatment

NCT ID: NCT01358864 Completed - Clinical trials for Hepatitis C, Chronic

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)

Start date: June 2011
Phase: Phase 3
Study type: Interventional

The aim of this trial is to evaluate the efficacy and the safety of BI 201335 given for 12 or 24 weeks in combination with PegIFN/RBV given for 48 weeks as compared to PegIFN/RBV alone in chronic GT-1 hepatitis C virus infected patients who failed a prior PegIFN/RBV treatment.

NCT ID: NCT01356160 Completed - Clinical trials for Hepatitis C, Chronic

GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus

Start date: July 2011
Phase: Phase 2
Study type: Interventional

This is a Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy with GS-5885 Alone or in Combination with GS-9451 with Peginterferon Alfa 2a and Ribavirin in Treatment Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection.

NCT ID: NCT01355289 Completed - Thrombocytopenia Clinical Trials

Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501

Start date: November 2011
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy of E5501 by measuring platelet response in subjects with chronic hepatitis C virus (HCV)-related thrombocytopenia who require antiviral treatment.

NCT ID: NCT01353911 Completed - Clinical trials for Hepatitis C, Chronic

Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)

Start date: June 27, 2011
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety, tolerability, and antiviral activity of grazoprevir (MK-5172) when administered in combination with peginterferon alfa-2b (Peg-IFN) and ribavirin (RBV) in treatment-naïve (TN) participants with chronic hepatitis C.

NCT ID: NCT01353248 Completed - Clinical trials for Hepatitis C, Chronic

GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection

Start date: May 2011
Phase: Phase 2
Study type: Interventional

The purpose of this phase 2 study is to determine whether 30 mg or 90 mg of GS-5885 when given with GS-9451, Tegobuvir and Ribavirin (RBV) for 12 or 24 weeks is effective, safe and tolerable in the treatment of Chronic Genotype 1 HCV Infection.

NCT ID: NCT01344889 Completed - Clinical trials for Hepatitis C, Chronic

An Observational Study on The Prediction of Adverse Events in Patients With Chronic Hepatitis C Receiving a Long-Acting Interferon Plus Ribavirin (GUARD-C)

Start date: October 2009
Phase: N/A
Study type: Observational

This observational study will assess factors leading to dose reductions/treatment discontinuations and the effect on sustained virological response in patients with chronic hepatitis C receiving a long-acting interferon (e.g. Pegasys/peginterferon alfa-2a) and ribavirin. Data will be collected from each patient for the duration of their treatment and for up to 6 months thereafter.